Stability Testing for Drug Substances and Drug Products

23/24 October 2024, Barcelona, Spain

Course No. 21464

header-image

Speakers

Dr. Thomas Fürst

Dr. Thomas Fürst

Boehringer Ingelheim

Dr. Josef Hofer

Dr. Josef Hofer

exdra

Dr. Cornelia Nopitsch-Mai

Dr. Cornelia Nopitsch-Mai

formerly Quality Assessor

Dr. Heiko Brunner

Dr. Heiko Brunner

Hamburg

Dr Thomas Uhlich

Dr Thomas Uhlich

Bayer

Dr Ulli Backofen

Dr Ulli Backofen

Boehringer Ingelheim

Objectives

This event is intended to provide information on different aspects of stability testing. The conference will be opened by an overview of stability testing with a special focus on important changes in current revisions of ICH Guidelines. In the subsequent presentations, important aspects of stability testing for biologicals and throughout drug development are discussed. The second day commences with a lecture on stability testing for Drug Substances, followed by a talk on Drug Products and a risk based approach for stability testing covering different climatic zones. In the following presentation, the focus lies on to the various aspects of submitting stability data. The specific challenges of data evaluation and typical questions from authorities will also be addressed. Finally, statistical considerations will be covered in another lecture.

Background

Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This conference will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results.

The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.

Finally, specifications for the API (drug substance), excipient(s) and the drug product are part of the quality section of the marketing authorisation application which has to be submitted to the competent authority.

Target Group

This conference is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities. Participants have the opportunity to exchange their experiences they gained with the different aspects of ‘specifications’ with the experts from the API and pharmaceutical industry as well as with members of competent authorities.

Programme

Stability Testing for Drug Substances and Drug Products

Seminar Programme as PDF

Current ICH and CHMP Guidelines for Stability Testing
  • Overview of Stability Guidelines
  • Concepts of Stability testing
  • Retest period and Shelf-life
  • Post-marketing Stability Studies
  • Future Activities
Stability Testing for Biologicals
  • Overview of regulatory requirements
  • Types of stability studies for Biopharmaceuticals
  • Practical aspects of stability studies with Biopharmaceuticals
  • Degradation pathways
  • Setting shelf life during early and late stage development
Stability Testing throughout Drug Development
  • Must the development stability programme meet ICH Q1A?
  • Stability testing from early development to product launch
  • Clinical stability for comparators
  • Site specific stability
Stability Testing for Drug Substances
  • Stability protocols
  • Stress testing
  • Photostability testing
  • Documentation
Stability Testing for Drug Products
  • Strategy of Stability Testing
  • Performance of new Drug Products
  • Related Finished Products with existing substances
  • Follow-up Stability Testing
Submitting Stability Data
  • Regulatory Strategy Stability
  • Drug Substance and Drug Product Stability Data and Evaluation
  • Storage recommendations/labelling/SmPC
  • Stability studies, commitments post approval
  • Typical questions from authorities and answers
Evaluation of Stability Results – Statistical Considerations
  • Sample number and replication
  • Trend analysis
  • Outliers
  • Pooling of batch data
  • Shelf life prediction
 
 

stop

This course is part of the GMP Certification Programme "ECA Certified Quality Control Manager" Learn more

ECA-Member*: € 1690,-
Non ECA Member*: € 1890,-
EU/GMP Inspectorates*: € 945,-
APIC Member Discount*: € 1790,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available
icon
Recording
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

"Great material and speakers" and "Great speakers a lot of experience and sharing"

Felipe Gonzalez, Mucos Emulsionsgesellschaft mbH
Live Online Training - Granulation & Tableting, September 2024

"Nice presentations: easy understanding, quite visual"

Susana Manrique, Boehringer Ingelheim España, S.A,
Live Online Training - Granulation & Tableting, September 2024

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023